Appili Therapeutics Inc's stock remains stable amidst recent announcements and strategic shifts.
This week, Appili Therapeutics Inc (APLI.TO) has seen no significant price movement, closing at C$0.01. The stock has remained unchanged over the past week, reflecting a broader trend of stability despite ongoing challenges in the healthcare sector. Investors are closely monitoring the company's strategic developments and financial performance.
Investor takeaway: While Appili Therapeutics has reported positive developments in its operational results and funding initiatives, the stock's performance remains lackluster. Investors should consider the company's strategic focus on biodefense and the implications of its financial results as they evaluate future prospects.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.32M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.19
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
357.9%
Annualized
90-Day Vol
278.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 โ C$0.03 |
| 60 trading days | C$0.01 | C$0.00 โ C$0.05 |
| 90 trading days | C$0.01 | C$0.00 โ C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
C$0.01
The stock has not moved from its last closing price, reflecting ongoing investor caution.
Bull case
Appili's recent US$40 million award from NIAID to advance its VXV-01 program through Phase 1 is a significant boost for the company. This funding, along with its strategic shift towards biodefense, positions Appili to potentially meet emerging market needs in infectious disease management.
Bear case
Despite the positive funding news, the stock has lost 60% year-to-date. With a negative return on equity and a profit margin of 0.0%, Appili faces serious financial challenges that could hinder its growth and recovery in the near term.
Price Action Overview
Appili Therapeutics Inc has experienced minimal price movement, closing at C$0.01, unchanged from the previous week. The stock has seen a significant decline of 60% year-to-date, while its monthly performance shows a decrease of 33.33%. Despite the recent stability, the overall trend indicates a challenging environment for the company.
Recent Company News
Advertisement
There have been several recent announcements from Appili Therapeutics, including its financial and operational results for fiscal year 2026, which highlighted progress in its commercial-stage programs. The company secured a US$40 million award from NIAID to advance its VXV-01 program through Phase 1, marking a significant milestone. Additionally, Appili has shifted its focus towards the biodefense sector, aiming to strengthen its position in health security.
Technical Picture
The technical indicators for Appili Therapeutics show a last close of C$0.01. The stock is currently below its 50-day moving average of C$0.01, which is down 19.4% compared to the current price, and significantly below its 200-day moving average of C$0.02, down 42.9%. The stock's 52-week range is C$0.01 to C$0.04, indicating it is currently trading at the lower end of this range. With a beta of -0.19, the stock has shown less volatility compared to the broader market.
Insider Activity
No recent insider activity has been reported for Appili Therapeutics, which may indicate a level of stability or uncertainty among insiders regarding future prospects.
Conclusion
In summary, Appili Therapeutics Inc remains at C$0.01, with no significant movement over the last week. The company's recent funding initiatives and strategic focus on biodefense provide a glimmer of hope, but the broader financial challenges and market conditions will likely continue to weigh on its stock performance.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
